Publication: CYP2D6 polymorphisms and their influence on risperidone treatment
4
Issued Date
2016-12-01
Resource Type
ISSN
11787066
Other identifier(s)
2-s2.0-85011068501
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmacogenomics and Personalized Medicine. Vol.9, (2016), 131-147
Suggested Citation
Apichaya Puangpetch, Natchaya Vanwong, Nopphadol Nuntamool, Yaowaluck Hongkaew, Monpat Chamnanphon, Chonlaphat Sukasem CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmacogenomics and Personalized Medicine. Vol.9, (2016), 131-147. doi:10.2147/PGPM.S107772 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/42747
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
CYP2D6 polymorphisms and their influence on risperidone treatment
Other Contributor(s)
Abstract
© 2016 Puangpetch et al. Cytochrome P450 enzyme especially CYP2D6 plays a major role in biotransformation. The interindividual variations of treatment response and toxicity are influenced by the polymorphisms of this enzyme. This review emphasizes the effect of CYP2D6 polymorphisms in risperidone treatment in terms of basic knowledge, pharmacogenetics, effectiveness, adverse events, and clinical practice. Although the previous studies showed different results, the effective responses in risperidone treatment depend on the CYP2D6 polymorphisms. Several studies suggested that CYP2D6 polymorphisms were associated with plasma concentration of risperidone, 9-hydroxyrisperidone, and active moiety but did not impact on clinical outcomes. In addition, CYP2D6 poor metabolizer showed more serious adverse events such as weight gain and prolactin than other predicted phenotype groups. The knowledge of pharmacogenomics of CYP2D6 in risperidone treatment is increasing, and it can be used for the development of personalized medication in term of genetic-based dose recommendation. Moreover, the effects of many factors in risperidone treatment are still being investigated. Both the CYP2D6 genotyping and therapeutic drug monitoring are the important steps to complement the genetic-based risperidone treatment.